# CJC-1295 Dosage in the Research Literature

> CJC-1295 dosage in the research: human PK studies used single 30, 60 or 90 ug/kg subcutaneous doses; mice received 2 ug. Half-life, route, and handling — research context only, not advice.

What was administered, to which species, at what dose, by which route. There is no approved human dose; what follows is the research record, reported as such, never a protocol to follow.

## Doses Used in the Published Research

CJC-1295 dosage in the published research is narrow and specific, and it is the only dosing this site reports. The human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram of body weight: Teichman and colleagues administered 30 and 60 micrograms per kilogram [1], and Ionescu and Frohman used 60 and 90 micrograms per kilogram [2]. These were dose-ranging pharmacokinetic studies in healthy volunteers, designed to characterize the GH and IGF-1 response, not to establish a therapeutic dose.

The animal work used very different amounts on a per-animal basis. In the GHRH-knockout mouse growth study, the dose was 2 micrograms per administration, given at 24-, 48-, or 72-hour intervals; only the once-every-24-hours schedule fully normalized growth [7]. The rat bioconjugate study used single subcutaneous boluses in a dose-ranging design to compare the albumin-conjugated lead against the unconjugated peptide [6].

The critical caveat is what these numbers are not. Community and clinic protocols for the no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin commonly cite fixed doses in the 100-300 microgram range, but those figures are not derived from controlled human trials [1]. There is no approved human dose for CJC-1295 in any form, and nothing on this page should be read as a recommendation.

### How much CJC-1295 should I take?

There is no approved human dose. Published research used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram in pharmacokinetic studies [1] [2]; community protocols of 100-300 micrograms are not derived from controlled human trials [1]. This is a research record, not guidance.

## Half-life, route, and how the studies framed timing

The dosing schedule in any GHRH-analog study is downstream of the half-life, and the two CJC-1295 forms could not be more different here. The DAC form's estimated half-life in healthy adults is 5.8 to 8.1 days, with IGF-1 elevation persisting up to 28 days after multiple doses [1] — which is why it was studied with infrequent administration. The no-DAC Modified GRF 1-29 is short-acting, in the minutes-to-hours range, reflecting native GHRH(1-29) clearance modified by the protease-resistant substitutions [6]. A dosing interval that suits one form makes no sense for the other.

The route studied is subcutaneous injection for the pharmacokinetic work, with the intravenous route used in early GRF(1-29) studies [1]. Oral bioavailability is negligible — CJC-1295 is a peptide and would be digested — so injection is the only route the literature characterizes [6]. None of this describes a human-use instruction; it describes how the studies were conducted.

### What injection route did the studies use?

The published pharmacokinetic studies used subcutaneous administration; early GRF(1-29) work also used the intravenous route [1]. This describes the research route only, not a human-use instruction.

### Where to inject CJC-1295?

The studies used subcutaneous injection as the characterized route [1]. The published literature describes the route used in research; it does not provide a site-of-injection instruction for human use.

## Handling and reconstitution in research settings

How CJC-1295 is handled in a research setting is straightforward and worth stating plainly. The peptide ships lyophilized — freeze-dried to a powder — and is reconstituted with bacteriostatic water and refrigerated in research handling [6]. The four amino-acid substitutions confer the DPP-IV and protease resistance that lets the molecule survive in plasma, and in the DAC form the albumin-conjugation chemistry confers the multi-day duration [6]. Oral bioavailability is negligible, which is why every characterized route is parenteral.

These are handling notes drawn from the research record, not instructions. They describe stability and preparation as the literature reports them, for the purpose of understanding how the compound was studied.

### How is CJC-1295 reconstituted and handled in research?

It ships lyophilized and is reconstituted with bacteriostatic water and refrigerated in research handling [6]; oral bioavailability is negligible, so subcutaneous injection is the route studied. This describes research handling, not a preparation protocol for human use.

For how the half-life difference shapes everything about timing, the [DAC vs no-DAC](/dac-vs-no-dac) page sets the two forms side by side, and the [study references](/references) page lists every source cited here.

---

An after-hours reading of the CJC-1295 literature — the GH and IGF-1 findings let breathe and cited to source, the multi-day DAC form held apart from the short-acting no-DAC one, and the empty long-term-safety line left openly unfilled; no clinic behind the lamplight and nothing here dispensed or sold.